Business Monitor International


Angola Pharmaceuticals & Healthcare Report

Published 18 August 2014

  • 61 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Angola Pharmaceuticals & Healthcare Report

BMI View: Both government and foreign investment will see the Angolan healthcare sector continue to grow in the coming years mainly due the country ' s rich oil reserves attracting external revenues. Angola ' s high burden of communicable disease, such as measles and malaria, will mean that the demand for vaccines remain high. However, the country ' s pharmaceutical and healthcare market is greatly affected by its difficult operating environment, with corruption and poor infrastructure posing considerable challenges to foreign drugmakers operating in the country.

Headline Expenditure Forecasts

  • Pharmaceuticals: AOA19.66bn (USD204mn) in 2013 to AOA21.95bn (USD223mn) in 2014; +11.7% in local currency and +9.6% in US dollar terms.

  • Healthcare: AOA437.04bn (USD4.53bn) in 2013 to AOA500.81bn (USD5.09bn) in 2014; +14.6% in local currency and +12.5% in US dollar terms.  Forecast revised downward to better suit current market conditions.

Risk/Reward Rating

Angola's Pharmaceutical Risk/Reward Rating (RRR) score for Q414 is 32.0, unchanged from last quarter. However, it drops one position making it the 27th most attractive pharmaceutical market in the Middle East and Africa region.

Key Trends And Developments

On July 22nd, Angolan Health minister José Van-Dunem, spoke at the opening session of the first Immunisation Meeting in Luanda. The purpose of the event was to inform families on campaigns, routine vaccinations and monitoring of preventable diseases via vaccine. According to Angop the minister stated, "We cannot achieve the goals envisaged unless the families take their children for vaccination campaigns," as he stressed the importance for them to value the government's effort on drug expenditure in ensuring a bright future for Angola. Other topics discussed included "Measles elimination" and the "coverage and introduction of new vaccines".

Also in July, it was reported by Angop during visits to Kwanzas market in Luanda, known to be the country's largest place...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Angola 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2010-2018)
19
Key Risks To BMI's Forecast Scenario
19
Macroeconomic Forecasts
21
Economic Analysis
21
Table: Angola - Economic Activity
25
Industry Risk Reward Ratings
26
Middle East & Africa
26
Angola Risk/Reward Ratings
34
Rewards
34
Risks
35
Market Overview
36
Industry Trends And Developments
38
Epidemiology
38
Clinical Trials
42
Regulatory Development
43
Regulatory Development
43
Intellectual Property Issues
44
Pricing Regime
44
Competitive Landscape
46
Company Developments
47
Company Profile
49
Nova Angom-dica
49
Demographic Forecast
51
Table: Angola's Population By Age Group, 1990-2020 ('000)
52
Table: Angola's Population By Age Group, 1990-2020 (% of total)
53
Table: Angola's Key Population Ratios, 1990-2020
54
Table: Angola's Rural And Urban Population, 1990-2020
54
Glossary
55
Methodology
57
Pharmaceutical Expenditure Forecast Model
57
Healthcare Expenditure Forecast Model
57
Notes On Methodology
58
Risk/Reward Ratings Methodology
59
Ratings Overview
60
Table: Pharmaceutical Risk/Reward Ratings Indicators
60
Indicator Weightings
61

The Angola Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Angola Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Angolan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Angola to test other views - a key input for successful budgeting and strategic business planning in the Angolan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Angolan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Angola.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc